Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
38.63
-0.27 (-0.69%)
Dec 20, 2024, 4:00 PM EST - Market closed
Xenon Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | - | - | 9.43 | 18.44 | 32.17 | 6.83 | Upgrade
|
| Revenue Growth (YoY) | - | - | -48.83% | -42.68% | 371.02% | - | Upgrade
|
| Cost of Revenue | 192 | 167.51 | 105.77 | 75.46 | 50.52 | 38.85 | Upgrade
|
| Gross Profit | -192 | -167.51 | -96.33 | -57.03 | -18.36 | -32.02 | Upgrade
|
| Selling, General & Admin | 63.52 | 46.54 | 32.81 | 21.97 | 12.94 | 10.8 | Upgrade
|
| Operating Expenses | 63.52 | 46.54 | 32.81 | 21.97 | 12.94 | 10.8 | Upgrade
|
| Operating Income | -255.52 | -214.05 | -129.14 | -78.99 | -31.3 | -42.82 | Upgrade
|
| Interest Expense | - | - | - | - | -0.48 | -1.43 | Upgrade
|
| Interest & Investment Income | 41.21 | 27.62 | 8.71 | 0.47 | 2.28 | 2.35 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.32 | 0.2 | -1.89 | 0.36 | 1.4 | 0.28 | Upgrade
|
| EBT Excluding Unusual Items | -213.98 | -186.24 | -122.32 | -78.17 | -28.11 | -41.62 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.15 | 3.55 | -2.93 | -0.72 | 0 | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -0.99 | - | Upgrade
|
| Pretax Income | -213.83 | -182.69 | -125.26 | -78.89 | -29.09 | -41.62 | Upgrade
|
| Income Tax Expense | -0.45 | -0.29 | 0.12 | -0.01 | -0.26 | -0.02 | Upgrade
|
| Net Income | -213.39 | -182.39 | -125.37 | -78.88 | -28.84 | -41.6 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | 0.44 | 1.8 | - | - | Upgrade
|
| Net Income to Common | -213.39 | -182.39 | -125.81 | -80.68 | -28.84 | -41.6 | Upgrade
|
| Shares Outstanding (Basic) | 76 | 67 | 61 | 44 | 36 | 29 | Upgrade
|
| Shares Outstanding (Diluted) | 76 | 67 | 61 | 44 | 36 | 29 | Upgrade
|
| Shares Change (YoY) | 15.16% | 10.48% | 38.77% | 21.09% | 23.57% | 8.92% | Upgrade
|
| EPS (Basic) | -2.82 | -2.73 | -2.08 | -1.85 | -0.80 | -1.43 | Upgrade
|
| EPS (Diluted) | -2.82 | -2.73 | -2.08 | -1.85 | -0.80 | -1.43 | Upgrade
|
| Free Cash Flow | -158.99 | -150.94 | -101.32 | -71.55 | -50.76 | -5.95 | Upgrade
|
| Free Cash Flow Per Share | -2.10 | -2.26 | -1.67 | -1.64 | -1.41 | -0.20 | Upgrade
|
| Gross Margin | - | - | - | - | -57.07% | - | Upgrade
|
| Operating Margin | - | - | -1368.91% | -428.45% | -97.31% | -627.02% | Upgrade
|
| Profit Margin | - | - | -1333.58% | -437.58% | -89.65% | -609.09% | Upgrade
|
| Free Cash Flow Margin | - | - | -1074.03% | -388.09% | -157.81% | -87.19% | Upgrade
|
| EBITDA | -252.74 | -210.51 | -127.52 | -78.09 | -30.66 | -42.39 | Upgrade
|
| EBITDA Margin | - | - | - | - | -95.31% | - | Upgrade
|
| D&A For EBITDA | 2.78 | 3.54 | 1.62 | 0.91 | 0.64 | 0.43 | Upgrade
|
| EBIT | -255.52 | -214.05 | -129.14 | -78.99 | -31.3 | -42.82 | Upgrade
|
| EBIT Margin | - | - | - | - | -97.31% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.